"Tumor Necrosis Factor-alpha" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Serum glycoprotein produced by activated MACROPHAGES and other mammalian MONONUCLEAR LEUKOCYTES. It has necrotizing activity against tumor cell lines and increases ability to reject tumor transplants. Also known as TNF-alpha, it is only 30% homologous to TNF-beta (LYMPHOTOXIN), but they share TNF RECEPTORS.
Descriptor ID |
D014409
|
MeSH Number(s) |
D12.644.276.374.500.800 D12.644.276.374.750.626 D12.776.124.900 D12.776.395.930 D12.776.467.374.500.800 D12.776.467.374.750.626 D23.529.374.500.800 D23.529.374.750.626
|
Concept/Terms |
Tumor Necrosis Factor-alpha- Tumor Necrosis Factor-alpha
- Tumor Necrosis Factor alpha
- Cachectin
- Cachectin-Tumor Necrosis Factor
- Cachectin Tumor Necrosis Factor
- Tumor Necrosis Factor Ligand Superfamily Member 2
- Tumor Necrosis Factor
- TNF Superfamily, Member 2
- TNFalpha
- TNF-alpha
|
Below are MeSH descriptors whose meaning is more general than "Tumor Necrosis Factor-alpha".
Below are MeSH descriptors whose meaning is more specific than "Tumor Necrosis Factor-alpha".
This graph shows the total number of publications written about "Tumor Necrosis Factor-alpha" by people in this website by year, and whether "Tumor Necrosis Factor-alpha" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
2001 | 0 | 1 | 1 |
2002 | 0 | 1 | 1 |
2004 | 1 | 0 | 1 |
2006 | 0 | 2 | 2 |
2007 | 0 | 3 | 3 |
2008 | 0 | 1 | 1 |
2009 | 0 | 1 | 1 |
2012 | 1 | 0 | 1 |
2013 | 0 | 2 | 2 |
2014 | 0 | 2 | 2 |
2016 | 1 | 2 | 3 |
2017 | 1 | 1 | 2 |
2018 | 2 | 1 | 3 |
2019 | 4 | 0 | 4 |
2020 | 0 | 1 | 1 |
2021 | 1 | 2 | 3 |
2022 | 1 | 2 | 3 |
To return to the timeline,
click here.
Below are the most recent publications written about "Tumor Necrosis Factor-alpha" by people in Profiles.
-
Longitudinal multi-omics analysis identifies early blood-based predictors of anti-TNF therapy response in inflammatory bowel disease. Genome Med. 2022 09 24; 14(1):110.
-
The long term vaccine-induced anti-SARS-CoV-2 immune response is impaired in quantity and quality under TNFa blockade. J Med Virol. 2022 Dec; 94(12):5780-5789.
-
Gene-selective transcription promotes the inhibition of tissue reparative macrophages by TNF. Life Sci Alliance. 2022 04; 5(4).
-
TNF-a-producing macrophages determine subtype identity and prognosis via AP1 enhancer reprogramming in pancreatic cancer. Nat Cancer. 2021 11; 2(11):1185-1203.
-
Early IFN-a signatures and persistent dysfunction are distinguishing features of NK cells in severe COVID-19. Immunity. 2021 11 09; 54(11):2650-2669.e14.
-
Urban living in healthy Tanzanians is associated with an inflammatory status driven by dietary and metabolic changes. Nat Immunol. 2021 03; 22(3):287-300.
-
Microglial activation in the dorsal striatum participates in anxiety-like behavior in Cyld knockout mice. Brain Behav Immun. 2020 10; 89:326-338.
-
Fragile X mental retardation protein protects against tumour necrosis factor-mediated cell death and liver injury. Gut. 2020 01; 69(1):133-145.
-
Metabolic Functions of Gut Microbes Associate With Efficacy of?Tumor Necrosis Factor Antagonists in Patients With Inflammatory Bowel Diseases. Gastroenterology. 2019 11; 157(5):1279-1292.e11.
-
Infliximab therapy together with tyrosine kinase inhibition targets leukemic stem cells in chronic myeloid leukemia. BMC Cancer. 2019 Jul 04; 19(1):658.